Mr M is switching ciclosporin brands due to manufacturing problem. What is the most appropriate advice?

• A. Monitor for toxicity or loss of efficacy
• B. Do nothing
• C. Stop therapy
• D. Switch back to original brand immediately

Answer: (A)

Switching ciclosporin formulations can change how much drug reaches the bloodstream because brands differ in bioavailability. With ciclosporin, exposure is closely tied to safety and efficacy, so small shifts can lead to toxicity (kidney injury, hypertension, neurotoxicity) or inadequate immunosuppression and risk organ rejection. The best advice is to monitor trough drug levels and the patient’s clinical response after the switch, and adjust the dose as needed to maintain the desired exposure. Alongside level checks, watch renal and liver function, blood pressure, and signs of infection or rejection, and counsel the patient on consistent dosing and possible new adverse effects. Other options fail to address the need for careful monitoring and potential dose adjustment, or neglect the risk of altered exposure.